-Identifies defective HRR signature regardless of cancer type
-Determines germline/somatic origin of pathogenic variants
-Assesses complex genomic profiles for synthetic lethality
-Supports treatment with PARP inhibitors, platinum agents
-Improves outcomes through precision therapy selection
By using an unbiased multi-gene approach, Minagene’s solution comprehensively interrogates the HRR pathway. Matched tumor-normal analysis guides definitive targeted therapy and enrollment in investigative clinical trials.